Consensus Medpace Holdings, Inc.

Stocks

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-11-06 EST			5-day change	1st Jan Change
653.11 ^USD	+2.86%		+0.17%	+16.28%

11-06	PriorNilsson Evolve Global fell 3.93% in October, industrial stocks weighed	FW
10-28	Medpace Holdings Insider Sold Shares Worth $13,540,000, According to a Recent SEC Filing	MT

Evolution of the Average Target: Medpace Holdings, Inc.

Evolution of the Target Price: Medpace Holdings, Inc.

Changes in Analyst Recommendations: Medpace Holdings, Inc.

b5d66d58966ecd72d90f983aa481.G68Y7YVUbA2nNKQWxeBmXC_OHhAKqcVqEPiAVZCQnzM.Tu53neYaNHrQUsthkNgSMUWFTVto9rEbSbTUPPvf6EJe1VS56Rk4X9ZlkA~95da5ba89dd97aaeeb2fd7e547b48a60

Analysts' recommendations: Medpace Holdings, Inc.

10-23	Medpace's Bookings, Pre-Backlog Trends Support Growth Outlook, UBS Says	MT
10-23	UBS Adjusts Price Target on Medpace to $700 From $673, Maintains Neutral Rating	MT
10-23	Truist Securities Adjusts Price Target on Medpace Holdings to $633 From $609, Keeps Hold Rating	MT
10-23	Analyst recommendations: Qiagen, Skydance, Moderna, PG&E, ServiceNow…
10-22	Deutsche Bank Adjusts Medpace Price Target to $650 From $535, Maintains Hold Rating	MT
09-30	UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $673 From $405	MT
08-21	Analyst recommendations: Equifax, Medpace Holdings, Applied Materials, PayPal, Moderna…
07-28	Analyst recommendations: Intuit, AMD, Fortinet, Globe Life…
07-24	Medpace's Bookings Recovery, Normalization of Cancellations Support Growth, RBC Says	MT
07-24	Truist Raises Price Target on Medpace Holdings to $609 From $462, Keeps Hold Rating	MT
07-24	RBC Raises Price Target on Medpace Holdings to $692 From $484, Keeps Outperform Rating	MT
07-24	Analyst recommendations: Netflix, Tapestry, Tesla, AMD, Intel…
07-23	Medpace jumps 15%, order rebound eases fears
07-23	Deutsche Bank Adjusts Medpace Price Target to $535 From $480, Maintains Hold Rating	MT
07-08	Medpace Shares Fall After Baird Downgrade	MT
07-08	Baird Downgrades Medpace to Neutral From Outperform, Adjusts PT to $547 From $477	MT
07-07	Medpace Shares Fall After Jefferies Downgrade	MT
07-07	Jefferies Downgrades Medpace Holdings to Hold From Buy, Adjusts Price Target to $515 From $490	MT
07-07	Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two…
04-24	Truist Adjusts Price Target on Medpace to $462 From $539, Maintains Hold Rating	MT
04-24	RBC Lowers Price Target on Medpace Holdings to $484 From $522, Keeps Outperform Rating	MT
04-23	Deutsche Bank Cuts Price Target on Medpace Holdings to $425 From $480, Keeps Hold Rating	MT
03-03	Medpace is Differentiated as Most Efficient Contract Research Organization, RBC Says	MT
03-03	RBC Initiates Medpace Holdings at Outperform With $522 Price Target	MT
02-18	Medpace Shares Rise After TD Cowen Upgrade	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MEDPACE HOLDINGS, INC.					-0.28%
	WUXI APPTEC CO., LTD.					+37.65%
	ARGENX SE					+23.19%
	LONZA GROUP AG					+7.56%
	BEONE MEDICINES AG					+7.52%
	IQVIA HOLDINGS INC.					+14.74%
	REVOLUTION MEDICINES, INC.					+35.98%
	CELLTRION, INC.					+29.95%
	GENMAB A/S					+13.61%
	INSMED INCORPORATED					+69.73%
	Average					+23.97%
	Weighted average by Cap.					+23.58%